ALK and non-small cell lung carcinoma: Tyrosine Kinase Inhibitors (TKIs), such as EGFR inhibitors (e.g., erlotinib and gefitinib) and ALK inhibitors (e.g., crizotinib and alectinib), have significantly improved outcomes for NSCLC patients [23].